Long-term outcome and predictors of outcome in patients with non-ischemic dilated cardiomyopathy

International Journal of Cardiology

Volumn 220, Issue , 2016, Pages 608-612

  Karatolios, Konstantinos ^a   Holzendorf, Volker ^b   Richter, Anette ^a   Schieffer, Bernhard ^a   Pankuweit, Sabine ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Dilated cardiomyopathy; Long term survival; Predictors of outcome

Indexed keywords

DIGITALIS;

ADULT; ARTICLE; ATRIAL FIBRILLATION; CONGESTIVE CARDIOMYOPATHY; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD ASSESSMENT; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; QTC INTERVAL; CARDIOMYOPATHY, DILATED; HEART STROKE VOLUME; LONG QT SYNDROME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; CARDIOMYOPATHY, DILATED; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84977142985     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.167     Document Type: Article

References (27)

1. [1] Jefferies, J.L., Towbin, J.A., Dilated cardiomyopathy. Lancet 375 (2010), 752–762, 10.1016/S0140-6736(09)62023-7.
2. [2] Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, P., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 29 (2008), 270–276, 10.1093/eurheartj/ehm342.
3. [3] Maron, B.J., Towbin, J.A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 (2006), 1807–1816, 10.1161/CIRCULATIONAHA.106.174287.
4. [4] Hofmann, T., Meinertz, T., Kasper, W., Geibel, A., Zehender, M., Hohnloser, S., et al. Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. Am. Heart J. 116 (1988), 1455–1463.
5. [5] Goldberger, J.J., Buxton, A.E., Cain, M., Costantini, O., Exner, D.V., Knight, B.P., et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation 123 (2011), 2423–2430, 10.1161/CIRCULATIONAHA.110.959734.
6. [6] Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., Roth, D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130 (1999), 461–470.
7. [7] Curtis, J.P., Sokol, S.I., Wang, Y., Rathore, S.S., Ko, D.T., Jadbabaie, F., et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. JACC 42 (2003), 736–742.
8. [8] Pocock, S.J., Wang, D., Pfeffer, M.A., Yusuf, S., McMurray, J.J.V., Swedberg, K.B., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur. Heart J. 27 (2006), 65–75, 10.1093/eurheartj/ehi555.
9. [9] Parker, A.B., Yusuf, S., Naylor, C.D., The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited. Am. Heart J. 144 (2002), 941–947, 10.1067/mhj.2002.126446.
10. [10] Solomon, S.D., Wang, D., Finn, P., Skali, H., Zornoff, L., McMurray, J.J.V., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 110 (2004), 2180–2183, 10.1161/01.CIR.0000144474.65922.AA.
11. [11] Solomon, S.D., Claggett, B., Desai, A.S., Packer, M., Zile, M., Swedberg, K., et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ. Heart Fail., 9, 2016, e002744, 10.1161/CIRCHEARTFAILURE.115.002744.
12. [12] Brooksby, P., Batin, P.D., Nolan, J., Lindsay, S.J., Andrews, R., Mullen, M., et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Eur. Heart J. 20 (1999), 1335–1341, 10.1053/euhj.1999.1542.
13. [13] Vrtovec, B., Delgado, R., Zewail, A., Thomas, C.D., Richartz, B.M., Radovancevic, B., Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 107 (2003), 1764–1769, 10.1161/01.CIR.0000057980.84624.95.
14. [14] Hombach, V., Merkle, N., Torzewski, J., Kraus, J.M., Kunze, M., Zimmermann, O., et al. Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy. Eur. Heart J. 30 (2009), 2011–2018, 10.1093/eurheartj/ehp293.
15. [15] Al-Ahmad, A., Rand, W.M., Manjunath, G., Konstam, M.A., Salem, D.N., Levey, A.S., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. JACC 38 (2001), 955–962.
16. [16] Hillege, H.L., Nitsch, D., Pfeffer, M.A., Swedberg, K., McMurray, J.J.V., Yusuf, S., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 (2006), 671–678, 10.1161/CIRCULATIONAHA.105.580506.
17. [17] Koga, Y., Wada, T., Toshima, H., Akazawa, K., Nose, Y., Prognostic significance of electrocardiographic findings in patients with dilated cardiomyopathy. Heart Vessel. 8 (1993), 37–41.
18. [18] Baldasseroni, S., Opasich, C., Gorini, M., Lucci, D., Marchionni, N., Marini, M., et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am. Heart J. 143 (2002), 398–405.
19. [19] Grimm, W., Christ, M., Bach, J., Müller, H.-H., Maisch, B., Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 108 (2003), 2883–2891, 10.1161/01.CIR.0000100721.52503.85.
20. [20] Sachero, A., Casazza, F., Recalcati, F., de Maria, R., Preti, L., Mattioli, R., et al. Clinical and prognostic significance of echocardiographic parameters in dilated cardiomyopathy: a prospective study on 225 patients. The Italian Multicenter Study of Cardiomyopathies Group. G. Ital. Cardiol. 22 (1992), 1077–1090.
21. [21] Goldberger, J.J., Subačius, H., Patel, T., Cunnane, R., Kadish, A.H., Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J. Am. Coll. Cardiol. 63 (2014), 1879–1889, 10.1016/j.jacc.2013.12.021.
22. [22] McMurray, J.J.V., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33 (2012), 1787–1847, 10.1093/eurheartj/ehs104.
23. [23] Linssen, G.C.M., Rienstra, M., Jaarsma, T., Voors, A.A., Van Gelder, I.C., Hillege, H.L., et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur. J. Heart Fail. 13 (2011), 1111–1120, 10.1093/eurjhf/hfr066.
24. [24] Blondheim, D.S., Jacobs, L.E., Kotler, M.N., Costacurta, G.A., Parry, W.R., Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am. Heart J. 122 (1991), 763–771.
25. [25] Koelling, T.M., Aaronson, K.D., Cody, R.J., Bach, D.S., Armstrong, W.F., Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am. Heart J. 144 (2002), 524–529.
26. [26] The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336 (1997), 525–533, 10.1056/NEJM199702203360801.
27. [27] Freeman, J.V., Yang, J., Sung, S.H., Hlatky, M.A., Go, A.S., Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ. Cardiovasc. Qual. Outcomes 6 (2013), 525–533, 10.1161/CIRCOUTCOMES.111.000079.